☰

Jeffrey McCombs - Publications

Affiliations: 
Pharmaceutical Economics and Policy University of Southern California, Los Angeles, CA, United States 
Area:
Pharmacy, General Economics
Tree Info Similar researchers PubMed Report error

44 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Han X, Fox DS, Chu M, Dougherty JS, McCombs J. Primary Prevention Using Cholesterol-Lowering Medications in Patients Meeting New Treatment Guidelines: A Retrospective Cohort Analysis. Journal of Managed Care & Specialty Pharmacy. 24: 1078-1085. PMID 30362921 DOI: 10.18553/Jmcp.2018.24.11.1078  0.31
2018 Ni W, Colayco D, Hashimoto J, Komoto K, Gowda C, Wearda B, McCombs J. Reduction of healthcare costs through a transitions-of-care program. American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. PMID 29650726 DOI: 10.2146/Ajhp170255  0.322
2018 Han X, McCombs J, Fox D, Chu M, Dougherty J. Secondary Prevention Using Cholesterol-Lowering Medications in Patients Meeting New Treatment Guidelines: A Retrospective Cohort Analysis Value in Health. 21. DOI: 10.1016/J.Jval.2018.04.025  0.361
2016 McGinnis J, McCombs J, Mehta D, Fox S, Tonnu-Mihara I. Analysis of the Impact of HIV Co-Infection on Hepatitis C Treatment Effectiveness for Patients Using New Direct-Acting Antivirals Journal of Hepatology. 64: S219-S220. DOI: 10.1016/S0168-8278(16)00191-4  0.322
2016 McCombs J, McGinnis J, Fox S, Tonnu-Mihara I. Analysis of the Real-World Effectiveness of Direct Acting Antiviral Treatments for Hepatitis C in a Large Population Journal of Hepatology. 64: S217. DOI: 10.1016/S0168-8278(16)00187-2  0.309
2016 Lee C, Chang J, Chou J, McCombs J. The Impact of Total Pill Burden on Treatment Adherence of Antiretroviral Therapy Value in Health. 19: A219-A220. DOI: 10.1016/J.Jval.2016.03.1180  0.354
2015 Jiang Y, Park S, McCombs J. The impact of alternative Antipsycontic Medications on the risk of adverse events in patients treated for Bipolar disorders Value in Health. 18: A115. DOI: 10.1016/J.Jval.2015.03.676  0.341
2015 Jiang Y, Park S, McCombs J. The impact of alternative Antipsychotic Medications on the risk of adverse events in patients treated for Schizophrenia Value in Health. 18: A115. DOI: 10.1016/J.Jval.2015.03.675  0.342
2015 McCombs J, Tonnu-Mihara I, Matsuda T, McGinnis J, Fox S. Can hepatitis c treatment be safely delayed?: evidence from the veterans administration healthcare system Value in Health. 18: A245. DOI: 10.1016/J.Jval.2015.03.1428  0.321
2014 McCombs J, Matsuda T, Tonnu-Mihara I, Saab S, Hines P, L'italien G, Juday T, Yuan Y. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. Jama Internal Medicine. 174: 204-12. PMID 24193887 DOI: 10.1001/Jamainternmed.2013.12505  0.3
2014 McCombs J, Matsuda T, Tonnu-Mihara I, Sasb S, Hines P, L'Italien G, Kalsekar A, Yuan Y. P761 THE IMPACT OF FIBROSIS ON THE RISK OF LONG-TERM MORBIDITY AND MORTALITY IN CHRONIC HEPATITIS C PATIENTS TREATED IN THE VETERANS ADMINISTRATION HEALTH CARE SYSTEM Journal of Hepatology. 60: S324. DOI: 10.1016/J.Jval.2014.03.1564  0.323
2012 Shin J, McCombs JS, Sanchez RJ, Udall M, Deminski MC, Cheetham TC. Primary nonadherence to medications in an integrated healthcare setting. The American Journal of Managed Care. 18: 426-34. PMID 22928758  0.522
2012 McCombs JS, Shin J, Hines P, Saab S, Yuan Y. Tu1014 Real-World Evaluation of the Economic Impact of Duration of Drug Therapy in the Treatment of Hepatitis C Virus (HCV): an Update Gastroenterology. 142: S-1011. DOI: 10.1016/S0016-5085(12)63913-4  0.586
2012 Shin J, Mccombs J, Udall M, Sanchez R, Deminski M, Cheetham C. PCV71 Primary Nonadherence to Cholesterol Medications and Associated Health Care Outcomes Value in Health. 15: A125. DOI: 10.1016/J.Jval.2012.03.674  0.577
2012 Shin J, McCombs J, Sanchez R, Udall M, Deminski M, Cheetham C. PHP20 Factors Associated With Primary Nonadherence to Chronic and Acute Medications Value in Health. 15: A16. DOI: 10.1016/J.Jval.2012.03.097  0.539
2011 McCombs JS, Yuan Y, Shin J, Saab S. Economic burden associated with patients diagnosed with hepatitis C. Clinical Therapeutics. 33: 1268-80. PMID 21840056 DOI: 10.1016/J.Clinthera.2011.07.008  0.536
2011 McCombs J, Zolfaghari S, Ganapathy V. Impact of drug treatment history on comparative effectiveness research in schizophrenia. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 14: 679-86. PMID 21839406 DOI: 10.1016/J.Jval.2011.02.002  0.415
2011 Shin J, Cheetham TC, Wong L, Niu F, Kass E, Yoshinaga MA, Sorel M, McCombs JS, Sidney S. The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system. Journal of the American Academy of Dermatology. 65: 1117-25. PMID 21565419 DOI: 10.1016/J.Jaad.2010.09.017  0.498
2011 McCombs JS, Shin J, Hines P, Saab S, Yuan Y. Real-World Evaluation of the Economic Impact of Duration of Drug Therapy in the Treatment of Hepatitis C Virus (HCV) Gastroenterology. 140: S-936. DOI: 10.1016/S0016-5085(11)63881-X  0.545
2011 McCombs JS, Shin J, Hines P, Saab S, Yuan Y. Impact of Newly Diagnosed Hepatitis C Infections on Health Care Costs Gastroenterology. 140: S-936. DOI: 10.1016/S0016-5085(11)63880-8  0.536
2011 McCombs J, Shin J, Hines P, Saab S, Yuan Y. PIN44 REAL-WORLD EVALUATION OF THE ECONOMIC IMPACT OF DURATION OF DRUG THERAPY IN THE TREATMENT OF HEPATITIS C VIRUS (HCV) Value in Health. 14: A121. DOI: 10.1016/J.Jval.2011.02.674  0.582
2011 McCombs J, Shin J, Saab S, Hines P, Yuan Y. PIN13 IMPACT OF NEWLY DIAGNOSED HEPATITIS C INFECTIONS ON HEALTH CARE COSTS Value in Health. 14: A116. DOI: 10.1016/J.Jval.2011.02.645  0.574
2011 Shin J, Cheetham C, Sanchez R, Deminski M, Udall M, Vansomphone S, McCombs J. PIH22 PRIMARY MEDICATION NONADHERENCE: A RETROSPECTIVE ANALYSIS OF ELECTRONIC PRESCRIPTIONS IN AN INTEGRATED HEALTHCARE SETTING Value in Health. 14: A109. DOI: 10.1016/J.Jval.2011.02.607  0.539
2010 Johnson KA, Chen S, Cheng IN, Lou M, Gregerson P, Blieden C, Baron M, McCombs J. The impact of clinical pharmacy services integrated into medical homes on diabetes-related clinical outcomes. The Annals of Pharmacotherapy. 44: 1877-86. PMID 21119101 DOI: 10.1345/Aph.1P380  0.335
2010 Shin J, Niu F, Wong L, Yoshinaga M, McCombs J, Cheetham C. PSS18 THE IMPACT OF THE IPLEDGE PROGRAM ON ISOTRETINOIN FETAL EXPOSURE Value in Health. 13: A149. DOI: 10.1016/S1098-3015(10)72721-2  0.502
2009 Marshall TS, McCombs JS, Stafkey-Mailey D. Impact of patient selection criteria and treatment history on comparisons of alternative therapies: a case study of atypical antipsychotics. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 12: 473-80. PMID 18798808 DOI: 10.1111/J.1524-4733.2008.00458.X  0.642
2008 Zolfaghari S, McCombs J, Stafkey-Mailey D, Ganapathy V, Kim E, Pikalov A. PMH75 IMPACT OF ALTERNATIVE TREATMENTS ON POST-TREATMENT COSTS FOR PATIENTS WITH SCHIZOPHRENIA Value in Health. 11: A132. DOI: 10.1016/S1098-3015(10)70421-6  0.7
2008 Zolfaghari S, McCombs J, Stafkey-Mailey D, Ganapathy V, Kim E, Pikalov A. PMH54 IMPACT OF ALTERNATIVE TREATMENTS ON DURATION OF DRUGTHERAPY BY PATIENTS WITH SCHIZOPHRENIA Value in Health. 11: A125-A126. DOI: 10.1016/S1098-3015(10)70401-0  0.34
2008 Ganapathy V, McCombs J, Stafkey-Mailey D, Kim E, Pikalov A. PMH53 IMPACT OF ALTERNATIVE TREATMENTS ON DURATION OF DRUGTHERAPY BY PATIENTS WITH BIPOLAR DISORDER Value in Health. 11: A125. DOI: 10.1016/S1098-3015(10)70400-9  0.654
2008 Stafkey-Mailey D, McCombs J, Hay J. A comparison of treatment-emergent diabetes among atypical and typical antipsychotic users European Psychiatry. 23: S148-S149. DOI: 10.1016/j.eurpsy.2008.01.898  0.609
2005 Ahn J, McCombs J, Jung C, Croudace T, McDonnell D, Ascher-Svanum H, Edgell E, Shi L. PMH55 CLASSIFYING ANTIPSYCHOTIC ADHERENCE USING LATENT CLASSES ANALYSIS: CHARACTERISTICS OF NON-ADHERENT CASEMIX IN THE CALIFORNIA MEDICAID (MEDICAL) PROGRAM Value in Health. 8: 401-402. DOI: 10.1016/S1098-3015(10)63090-2  0.305
2004 McCombs JS, Mulani P, Gibson PJ. Open access to innovative drugs: treatment substitutions or treatment expansion? Health Care Financing Review. 25: 35-53. PMID 15229995  0.572
2004 McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 48: 271-87. PMID 15207894 DOI: 10.1016/J.Maturitas.2004.02.005  0.555
2003 McCombs J, Thiebaud P, McLaughlin-Miley C. Pari 3: Compliance With Drug Therapies For The Treatment And Prevention Of Osteoporosis Value in Health. 6: 224-225. DOI: 10.1016/S1098-3015(10)63914-9  0.351
2001 Lyu RR, McCombs JS, Johnstone BM, Muse DN. Use of conventional antipsychotics and the cost of treating schizophrenia. Health Care Financing Review. 23: 83-99. PMID 12500340  0.311
2001 Shi J, McCombs J, Hay J, Nichol M, Chou C, Hsiao C. PMA7: CONTROLLING FOR BIASES FROM MEASUREMENT ERRORS IN HEALTH OUTCOMES RESEARCH USING STRUCTURAL EQUATION MODELING Value in Health. 4: 183-184. DOI: 10.1046/J.1524-4733.2001.40202-301.X  0.536
2001 Mulani P, McCombs J. MH1: THE IMPACT OF SECOND-GENERATION ANTIPSYCHOTIC MEDICATIONS ON AMBULATORY PATIENTS WITH SCHIZOPHRENIA Value in Health. 4: 61. DOI: 10.1046/J.1524-4733.2001.40201-37.X  0.431
2000 McCombs JS, Nichol MB, Johnstone BM, Stimmel GL, Shi J, Smith R. Antipsychotic drug use patterns and the cost of treating schizophrenia. Psychiatric Services (Washington, D.C.). 51: 525-7. PMID 10737831 DOI: 10.1176/Appi.Ps.51.4.525  0.563
1999 McCombs JS, Nichol MB, Stimmel GL, Shi J, Smith RR. Use patterns for antipsychotic medications in medicaid patients with schizophrenia. The Journal of Clinical Psychiatry. 60: 5-11; discussion 12-. PMID 10507275  0.518
1999 McCombs J, Luo M, Shi L. PNP16: ANTIPSYCHOTIC DRUG USE PATTERNS AND THE COST OF TREATING SCHIZOPHRENIA OVER A 2-YEAR PERIOD Value in Health. 2: 174. DOI: 10.1016/S1098-3015(11)70941-X  0.323
1999 Venturini F, Nichol M, McCombs J, Sengupta N, Kamath T, Tannous R. TPCP5: THE COST OF DISCONTINUATION OF ANTI-HYPERTENSIVE DRUG THERAPY IN A MEDICAID POPULATION Value in Health. 2: 148-149. DOI: 10.1016/S1098-3015(11)70875-0  0.319
1998 McCombs JS, Liu G, Shi J, Feng W, Cody M, Parker JP, Nichol MB, Hay JW, Johnson KA, Groshen SL, Nye MT. The Kaiser Permanente/USC Patient Consultation Study: change in use and cost of health care services. American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 55: 2485-99. PMID 9853633 DOI: 10.1093/Ajhp/55.23.2485  0.56
1998 McCombs J, Nichol M. PMH5 The Cost of Treating Schizophrenia in the California Medicaid (MEDI-CAL) Program Value in Health. 1: 79-80. DOI: 10.1046/J.1524-4733.1998.1100785.X  0.447
1994 McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Medical Care. 32: 214-26. PMID 8145599  0.32
Show low-probability matches.